Ardena, a Contract Development and Manufacturing Organization (CDMO) specializing in bringing molecules to clinic, has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new analytical laboratories in its expanded nanomedicines facility.
Ardena Bolsters US Business Development with Key Appointment in the East Coast
Race Oncology Ltd. signed an agreement with Ardena Holding NV, global CDMO, to provide additional good manufacturing practice (cGMP)-standard manufacturing capability for Race's flagship intravenous (IV) formulation of bisantrene, RC220.
Ardena, a contract development manufacturer of nanomedicine, has joined forces with mRNA and LNP technology specialists RiboPro to form a new strategic commercial alliance aimed at delivering improvements to the global availability of RNA-based health treatments and address a crucial skills gap in the industry.
Ardena Appoints Christian Renken as Business Development Director West Coast
Celebrating a milestone of our new Nanomedicines facility
Ardena Joins EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs
Ardena, a fully integrated Contract Development and Manufacturing Organization (CDMO) assisting biopharma companies with services spanning across the development life cycle, will nearly triple the size of its Swedish facility as part of its €35 million ($34.7 million) investment across its European operations.
Fully integrated Contract Development and Manufacturing Organisation (CDMO) has announced upgrades to its development and manufacturing facilities in Pamplona (Spain), with investments in dry granulation technology, and upgrades to its spray drying capabilities.